HIV Slide Set
Treatment of Human Immunodeficiency Viruses Infection
Therapy of HIV is complicated by the fact that the HIV genome is incorporated into the host cell genome and can remain there in a dormant state for prolonged periods until it is reactivated. Effective therapy must be directed against both free virus and virus-infected cells. Although a number of substances with in vitro anti-HIV activity have been described, only a few drugs exhibit anti-HIV activity in vivo at tolerable toxicities. The main group of substances described are;
1. Nucleoside analogues reverse transcriptase inhibitors. AZT, DDC, DDI and lamuvidine.
2. Non-nucleoside analogue reverse transcriptase inhibitors e.g. Nevirapine
3. HIV Protease inhibitors e.g. Ritonavir, Indivavir. They are the most potent inhibitors of HIV replication to date.
Zidovudine (AZT) was the first anti-viral agent shown to have beneficial effect against HIV infection. However, after prolonged use, AZT-resistant strains rapidly appears which limits the effect of AZT. Recent clinical trials reported significant benefit in the use of combination therapy over the use of monotherapy. The rationale for this approach is that by combining drugs that are synergistic, non-cross-resistant and no overlapping toxicity, it may be possible to reduce toxicity, improve efficacy and prevent resistance from arising. In fact, significant success has now been reported for trials involving multiple agents including protease inhibitors. The aim of anti-HIV therapy has now shifted from simply delaying the progression of disease to finding a permanent cure. We have now entered the era of highly active anti-retroviral therapy (HAART).
The current consensus is that one should give a potent combination of agents HAART right from the start when treatment is indicated. The most popular combination is AZT and lamivudine plus a protease inhibitor. Lamivudine has greater anti-retroviral activity that AZT alone and is active against many AZT-resistant strains without significant increase in toxicity.. Among protease inhibitors, indinavir (IDV) is more potent than saquinavir and appears to have fewer drug interactions and short-term adverse effects than ritonavir. In currently recommended doses, AZT prophylaxis is well-tolerated with health workers; short-term toxicity associated with higher doses primarily includes GI symptoms, fatigue, and headache. In HIV-infected adults, 3TC can cause GI symptoms, and rarely pancreatitis. IDV toxicity includes GI symptoms and after prolonged use, mild hyperbilirubinaemia (10%), and kidney stones (4%).Below is a table of some of the drugs available.
It is generally agreed that treatment should be started when
CD4<500/ml or viral load >5000 to 10000 copies/ml (bDNA
assay). If CD4 count >500/ml but viral load >5000 to 10000
copies/ml (bDNA assay), then recommendations vary. It may then be
advisable to treat those who are compliant and committed.
A. Nucleoside Reverse Transcriptase Inhibitor
|200 mg po or
125-250 mg bd
0.75 mg q8h
30-40 mg bd
150 mg bd
300 mg bd
suppression (anaemia, granulocytopenia), headache,
Pancreatitis, peripheral neuropathy, minor GI and CNS symptoms
Peripheral neuropathy, oral ulcers, minor GI and CNS symptoms
Peripheral neuropathy, minor GI and CNS symptoms
Well-tolerated, minor GI and CNS symptoms reported may be due to AZT rather than 3TC. Pancreatitis was reported in 15% of patients in paediatric trials
3% develop hypersensitivity reaction: fever malaise, rash, GI symptoms.
B. Non-Nucleoside Reverse Transcriptase Inhibitor
|200 mg po (single
dose), then 400 mg/day
400 mg qds
600mg once daily
Transient rash, P450 inhibitor
Initial dizziness, insomnia, transient rash, P450 inducer
C. HIV Protease Inhibitors
|600 mg tds
800mg po tds
600 mg po bd
750 mg tds
1200 mg bd
kidney stones, bilirubinaemia
Although side-effects are common, they are usually mild and consist mainly of GI symptoms
Diarrhoea common, which may respond to Ultrase MT20 enzyme preparations; occasional nausea
Rash (20%), diarrhoea, nausea
Monitoring anti-HIV therapy
1. Viral Load
Initiation - viral load is now the preferred method of monitoring therapy. There should be >= 1 log reduction in viral load, preferably to less than 10,000 copies/ml HIV-RNA within 2-4 weeks after the commencement of treatment. If <0.5 log reduction in viral, or HIV-RNA stays above 100,000, then the treatment should be adjusted by either adding or switching drugs.
Monitoring - viral load measurement should be repeated every 4-6 months if patient is clinically stable. If viral load returns to 0.3-0.5 log of pre-treatment levels, then the therapy is no longer working and should be changed.
2. CD4 count
Initiation - within 2-4 weeks of starting treatment, CD4 count should be increased by at least 30 cells/mm3. If this is not achieved, then the therapy should be changed..
Monitoring - CD4 counts should be obtained every 3-6 months during periods of clinical stability, and more frequently should symptomatic disease occurs. If CD4 count drops to baseline (or below 50% of increase from pre-treatment), then the therapy should be changed
As a result of HAART, mortality from HIV has declined
continuously in the N. America and Europe. However, the long term
outlook remains uncertain. These drugs are very expensive and the
patient needs to take them for life. Therefore, there is a
question of compliance. It had been suggested that it would take
at least 7 to 10 years to eliminate all HIV particles in an
The risk of contracting HIV increases with the number of sexual partners. It is interesting to note that the first cases of AIDS which were reported in homosexuals admitted to having more than 100 sexual partners per year. A change in the lifestyle would obviously reduce the risk. Paediatric AIDS generally occur early in life although some children have survived congenital infection for many years. Infected infants may serve as worldwide reservoirs of AIDS if they survive infancy, as in the case of hepatitis B.
HIV-infected mothers are not recommended to have children at present and pregnancy itself would appear to be a risk factor for seropositive mothers. A recent clinical trial demonstrated the efficacy of AZT in preventing transmission of HIV from the mother to the fetus. The incidence of HIV infection in the baby was reduced by two-thirds. The regimen used in this trial included antenatal oral administration of AZT beginning at 14-34 weeks of gestation and continuing throughout pregnancy, followed by intrapartum IV AZT, and postnatal oral AZT to the infant for 6 weeks after delivery.
The spread of HIV through blood transfusion had virtually been
eliminated since the introduction of blood donor screening in
many countries. It must be borne in mind that recently infected
donors who have yet to develop antibodies will escape detection.
There had also been recent reports of new virus isolates from
patients serologically negative for HIV, yet who may have AIDS-
related symptoms. Blood products such as factor VIII now undergo
routine treatment which appears to inactivate any HIV present
An effective vaccine against HIV would have to elicit protection against both free virus and virus-infected cells. HIV neutralizing antibodies. Several examples of retroviral infections eg. FeLV, suggest that neutralizing antibodies on its own may be protective. The observation that HIV-neutralizing antibodies do not prevent the progression of the disease and the induction of neutralizing antibodies in chimpanzees by HIV gp160 do not prevent infection by HIV argues against the possibility that neutralizing antibodies are sufficient for protection against infection by HIV. Individuals with high neutralizing antibody titres, however, seem to have a longer disease free interval. Cellular immune response may be important for protection and may take place through Tc cells, NK cells and ADCC mechanisms. The role of these mechanisms in the protection against HIV infection and their relevance for anti-HIV vaccination are still unclear.
Another obstacle to the development of an effective HIV vaccine may be the high genetic variability of HIV, which resides mainly in the env gene. In certain regions of the envelope gene, the variability may be as high as 50%. However, conserved regions exist in the gp120 and the gp41 region which can be recognized by HIV sera and neutralizing antibodies can be induced with peptides representing these regions. The main types of approaches to an AIDS vaccine is as follows:
Because of the serious nature of the disease and the ability of retroviruses to induce latency, it is unlikely that live attenuated or inactivated virus will ever be acceptable for human use. Live recombinant viruses such as vaccinia or adenovirus recombinant have been developed for HIV vaccination. They carry a high immunogenicity since virus replication result in large quantities of virus antigen. Both humoral and cellular immunity can be induced. A disadvantage of this approach is possible adverse effects observed after inoculation of vaccinia virus.
Synthetic peptides can be designed such that
neutralizing and T cell epitopes can be included. The problems
with synthetic peptides are related to the tertiary structures
which may be different from those of native proteins. Another
promising approach is the production of recombinant viral
antigens, especially the gene products of the env region, and the
membrane associated p17 core protein. An alternative approach
would be the use of anti-idiotype antibodies whose usefulness had
been demonstrated against several infectious agents. Passive
immunization may eventually be available for postexposure
protection. To-date, it looks like that the best hope lies in an
inactivated vaccine. Trials are being conducted with this vaccine
HIV Slide Set